Vir Biotechnology Inc
VIR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.46B
Close$
$12.26
37.7% upside
Current Fair Value
37.7% upsideUndervalued by 37.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.46 Billion |
|---|---|
| Enterprise Value | $1.27 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.16 |
| Beta | 1.62 |
| Outstanding Shares | 147,356,811 |
Return
| Return on Equity | -54.47% |
|---|---|
| Return on Assets | -43.17% |
| Return on Invested Capital | -49.08% |
Valuation & Multiples
| P/E Ratio | -2.77 |
|---|---|
| PEG | -70.76 |
| Price to Sales | - |
| Price to Book Ratio | 1.78 |
| Enterprise Value to Revenue | 19.41 |
| Enterprise Value to EBIT | -2.72 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$58.23 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.33
Average shareholder expectationRevenue Estimate
$135.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 92.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.53%▼ 92.13% |
|---|---|
| Total Invested | $38.03M▼ 96.95% |
| Investors Holding | 47▼ 215.00% |
ESG Score
No data
About Vir Biotechnology Inc
327 employeesVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are desi...